The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m.sup.2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.

Methods for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer, based on the presence of certain structures associated with circulating cancer associated macrophage-like cells (CAMLs), including micronuclei (MN), extracellular vesicles (EVs), enlarged polynuclearization (EPN), internalized intact cells and large internal cellular debris, are provided.

The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.

A kit useful for determination of canine TK1 in a sample is disclosed. The kit comprises a first monoclonal antibody, or a fragment thereof, immobilized to a support or intended to be immobilized to a support. The kit also comprises a second monoclonal antibody, or a fragment thereof. One of the monoclonal antibodies has specificity for a peptide consisting of an amino acid sequence from a C-terminal region of canine TK1 and the other monoclonal antibody has specificity for a peptide consisting of an amino acid sequence from an active site of TK1.

The present disclosure generally relates to systems and methods for partitioning species. In some embodiments, such systems can be used for determining one or more types of cancer. For example, certain aspects are generally directed to aqueous multi-phase partitioning systems that can be used, for example, for distinguishing between different types of cancers, diagnosing subjects with cancer, or the like. In some cases, such systems can be identified using solvent properties such as the solvent dipolarity/polarizability difference (*), the solvent hydrogen bond donor acidity difference (), the solvent hydrogen bond acceptor basicity difference (), and the electrostatic property difference (c) between two phases of the partitioning system. These may be within certain ranges in accordance with various embodiments.

The present invention relates to a method for detecting a particulate substance by immunochromatography, the particulate substance including, on its surface, a plurality of substances to be bound containing a first substance to be bound and a second substance to be bound which may be the same or different with respect to each other, wherein the method includes the steps of: (1) contacting on a membrane a sample containing the particulate substance with a first specific binding substance for the first substance to be bound to capture the particulate substance with the first specific binding substance; (2) contacting the captured particulate substance with a second specific binding substance for the second substance to be bound to label the particulate substance; and (3) detecting the labeled particulate substance, wherein the first specific binding substance is immobilized on the membrane, and the second specific binding substance is bound to a metal nanoparticle.

A method of collecting data for diagnosing cancer, determining an onset risk, determining a malignancy grade, and/or predicting a prognosis of cancer according to the present disclosure includes the steps of bringing a sample derived from a subject into contact with tumor-associated antigens to cause an antigen-antibody reaction; measuring an amount of anti-p53 antibody, in the sample, that specifically binds to any of the tumor-associated antigens; and comparing the measured amount of the anti-p53 antibody with a predetermined reference level of the anti-p53 antibody against the tumor-associated antigens. The tumor-associated antigens include one or more p53 isoform variants consisting of amino acid sequences having a mutation in an amino acid sequence of any one of SEQ ID NOs: 1 to 3, and the mutation includes any one of an N-terminal deletion mutation, a C-terminal deletion mutation, and both the N-terminal deletion and the C-terminal deletion mutation.

Provided are a cancer therapeutic drug comprising a compound which inhibits GPX4 as an active ingredient, the cancer therapeutic drug treating cancer containing a cancer cell having a suppressed function of a SWI/SNF complex factor detected; and a method for predicting sensitivity of a cancer cell to a GPX4 inhibitor, the method comprising the step of predicting a cancer cell having a suppressed function of a SWI/SNF complex factor detected in the cancer cell, as having sensitivity to the GPX4 inhibitor.

Disclosed herein are methods for detecting or determining an amount, quantity, concentration and/or level of an anti-transcription factor A, mitochondrial (TFAM) antibody, such as an anti-human TFAM antibody, in one or more biologics samples obtained from a subject. In some aspects, the methods relate to identifying a subject suffering from systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome that is at risk of thrombosis, malignancy, death or any combination thereof.

The present invention relates to methods for identifying and detecting potential disease specific biomarkers from biofluids. In particular, the methods involve in vivo administration of nanoparticles to a subject in a diseased state or incubating nanoparticles in a biofluid sample taken from a subject in a diseased state and analysis of the biomolecule corona formed on said nanoparticles. In addition, the present invention also relates to methods that provide a means to distinguish between a healthy and diseased state in a subject, such as for example the presence of a tumor in a human subject.